exagen inc - XGN

XGN

Close Chg Chg %
6.01 0.07 1.16%

Closed Market

6.08

+0.07 (1.16%)

Volume: 1.07M

Last Updated:

Dec 31, 2025, 4:00 PM EDT

Company Overview: exagen inc - XGN

XGN Key Data

Open

$6.03

Day Range

5.93 - 6.13

52 Week Range

2.67 - 12.23

Market Cap

$137.79M

Shares Outstanding

22.66M

Public Float

15.32M

Beta

1.87

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.93

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

299.46K

 

XGN Performance

1 Week
 
-0.82%
 
1 Month
 
-15.56%
 
3 Months
 
-44.53%
 
1 Year
 
48.29%
 
5 Years
 
-53.94%
 

XGN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About exagen inc - XGN

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

XGN At a Glance

Exagen, Inc.
1261 Liberty Way
Vista, California 92081
Phone 1-760-560-1501 Revenue 55.64M
Industry Medical/Nursing Services Net Income -15,115,000.00
Sector Health Services 2024 Sales Growth 5.886%
Fiscal Year-end 12 / 2025 Employees 209
View SEC Filings

XGN Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.341
Price to Book Ratio 7.581
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.377
Enterprise Value to Sales 1.365
Total Debt to Enterprise Value 0.308

XGN Efficiency

Revenue/Employee 266,224.88
Income Per Employee -72,320.574
Receivables Turnover 7.102
Total Asset Turnover 1.087

XGN Liquidity

Current Ratio 2.699
Quick Ratio 2.275
Cash Ratio 1.632

XGN Profitability

Gross Margin 59.51
Operating Margin -24.507
Pretax Margin -27.144
Net Margin -27.165
Return on Assets -29.539
Return on Equity -93.783
Return on Total Capital -45.938
Return on Invested Capital -39.846

XGN Capital Structure

Total Debt to Total Equity 244.895
Total Debt to Total Capital 71.006
Total Debt to Total Assets 51.464
Long-Term Debt to Equity 226.866
Long-Term Debt to Total Capital 65.778
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Exagen Inc - XGN

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
48.30M 45.56M 52.55M 55.64M
Sales Growth
+15.07% -5.66% +15.33% +5.89%
Cost of Goods Sold (COGS) incl D&A
20.59M 24.21M 23.09M 22.53M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
948.00K 2.11M 2.17M 1.72M
Depreciation
948.00K 2.11M 2.17M 1.72M
Amortization of Intangibles
- - - -
-
COGS Growth
+24.33% +17.61% -4.63% -2.44%
Gross Income
27.71M 21.35M 29.46M 33.11M
Gross Income Growth
+9.03% -22.96% +37.97% +12.41%
Gross Profit Margin
+57.37% +46.86% +56.06% +59.51%
2021 2022 2023 2024 5-year trend
SG&A Expense
51.78M 61.89M 52.29M 46.75M
Research & Development
7.24M 9.88M 4.87M 5.38M
Other SG&A
44.54M 52.02M 47.43M 41.37M
SGA Growth
+28.16% +19.54% -15.51% -10.60%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 5.51M
-
EBIT after Unusual Expense
(24.07M) (46.05M) (22.84M) (13.64M)
Non Operating Income/Expense
16.00K 830.00K 1.52M 767.00K
Non-Operating Interest Income
- 830.00K 1.52M 767.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.63M 2.45M 2.33M 2.23M
Interest Expense Growth
+2.34% -6.74% -4.62% -4.33%
Gross Interest Expense
2.63M 2.45M 2.33M 2.23M
Interest Capitalized
- - - -
-
Pretax Income
(26.68M) (47.67M) (23.66M) (15.10M)
Pretax Income Growth
-59.11% -78.70% +50.37% +36.16%
Pretax Margin
-55.23% -104.62% -45.02% -27.14%
Income Tax
175.00K (282.00K) 33.00K 12.00K
Income Tax - Current - Domestic
27.00K 24.00K 33.00K 12.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - 148.00K (306.00K)
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(26.85M) (47.39M) (23.69M) (15.12M)
Minority Interest Expense
- - - -
-
Net Income
(26.85M) (47.39M) (23.69M) (15.12M)
Net Income Growth
-60.91% -76.48% +50.01% +36.19%
Net Margin Growth
-55.59% -104.00% -45.08% -27.17%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(26.85M) (47.39M) (23.69M) (15.12M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(26.85M) (47.39M) (23.69M) (15.12M)
EPS (Basic)
-1.6811 -2.774 -1.3399 -0.8304
EPS (Basic) Growth
-27.46% -65.01% +51.70% +38.03%
Basic Shares Outstanding
15.97M 17.08M 17.68M 18.20M
EPS (Diluted)
-1.6811 -2.774 -1.3399 -0.8304
EPS (Diluted) Growth
-27.46% -65.01% +51.70% +38.03%
Diluted Shares Outstanding
15.97M 17.08M 17.68M 18.20M
EBITDA
(23.12M) (38.44M) (20.67M) (11.91M)
EBITDA Growth
-60.11% -66.26% +46.23% +42.37%
EBITDA Margin
-47.87% -84.36% -39.33% -21.41%

Snapshot

Average Recommendation BUY Average Target Price 15.429
Number of Ratings 8 Current Quarters Estimate -0.167
FY Report Date 03 / 2026 Current Year's Estimate -0.462
Last Quarter’s Earnings -0.176 Median PE on CY Estimate N/A
Year Ago Earnings -0.879 Next Fiscal Year Estimate -0.222
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 6
Mean Estimate -0.17 -0.12 -0.46 -0.22
High Estimates -0.13 -0.09 -0.29 0.03
Low Estimate -0.25 -0.22 -0.90 -0.68
Coefficient of Variance -22.46 -36.82 -42.25 -120.80

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Exagen Inc - XGN

Date Name Shares Transaction Value
Mar 28, 2025 Sun Mountain Capital Advisors, LLC 1,758,958 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $3.3 per share 5,804,561.40
Feb 26, 2025 Jeffrey G. Black Chief Financial Officer 289,492 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 Jeffrey G. Black Chief Financial Officer 10,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 John Aballi President and CEO; Director 737,593 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 26, 2025 John Aballi President and CEO; Director 75,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Exagen Inc in the News